NASDAQ:TXMD TherapeuticsMD (TXMD) Stock Price, News & Analysis $2.06 +0.03 (+1.48%) As of 08/20/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About TherapeuticsMD Stock (NASDAQ:TXMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TherapeuticsMD alerts:Sign Up Key Stats Today's Range$2.01▼$2.0750-Day Range$1.94▼$2.2952-Week Range$0.99▼$2.95Volume25,510 shsAverage Volume19,549 shsMarket Capitalization$23.83 millionP/E Ratio103.00Dividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview TherapeuticsMD, Inc. (NASDAQ:TXMD) is a women's healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies. Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause. The company also markets BIJUVA, the first combination bio-identical estrogen and progesterone capsule for the treatment of moderate to severe hot flashes. In addition, TherapeuticsMD is advancing a pipeline of novel contraceptive technologies, including transdermal delivery systems and oral formulations aimed at providing more flexible dosing options. Founded in 2015 and headquartered in Boca Raton, Florida, TherapeuticsMD has built a leadership team with extensive experience in women’s health and specialty pharmaceuticals. The organization emphasizes strategic partnerships and targeted clinical development to support product launches and lifecycle management. With a commitment to research and patient-centric care, TherapeuticsMD continues to expand its portfolio and strengthen its position in the women’s health market.AI Generated. May Contain Errors. Read More TherapeuticsMD Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreTXMD MarketRank™: TherapeuticsMD scored higher than 19% of companies evaluated by MarketBeat, and ranked 814th out of 914 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingTherapeuticsMD has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageTherapeuticsMD has only been the subject of 1 research reports in the past 90 days.Read more about TherapeuticsMD's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of TherapeuticsMD is 103.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.55.Price to Earnings Ratio vs. SectorThe P/E ratio of TherapeuticsMD is 103.00, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 268.95.Price to Book Value per Share RatioTherapeuticsMD has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.26% of the float of TherapeuticsMD has been sold short.Short Interest Ratio / Days to CoverTherapeuticsMD has a short interest ratio ("days to cover") of 1.36, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TherapeuticsMD has recently decreased by 32.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTherapeuticsMD does not currently pay a dividend.Dividend GrowthTherapeuticsMD does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 1 people have searched for TXMD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added TherapeuticsMD to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TherapeuticsMD insiders have not sold or bought any company stock.Percentage Held by Insiders1.70% of the stock of TherapeuticsMD is held by insiders.Percentage Held by Institutions30.74% of the stock of TherapeuticsMD is held by institutions.Read more about TherapeuticsMD's insider trading history. Receive TXMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TXMD Stock News HeadlinesTherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gainsJune 5, 2026 | marketwatch.comTherapeuticsMD Reports Quarterly Profit, Evaluates Strategic AlternativesMay 12, 2026 | tipranks.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | Porter & Company (Ad)TherapeuticsMD Announces First Quarter 2026 Financial ResultsMay 12, 2026 | businesswire.comTherapeuticsMD Inc. stock outperforms competitors on strong trading dayApril 6, 2026 | marketwatch.comTherapeuticsMD Narrows 2025 Loss, Advances Royalty StrategyApril 2, 2026 | theglobeandmail.comTherapeuticsMD Explains Brief Delay In Annual FilingApril 1, 2026 | tipranks.comTherapeuticsMD Announces Full Year 2025 Financial ResultsMarch 30, 2026 | finance.yahoo.comSee More Headlines TXMD Stock Analysis - Frequently Asked Questions How have TXMD shares performed this year? TherapeuticsMD's stock was trading at $1.63 at the start of the year. Since then, TXMD shares have increased by 26.4% and is now trading at $2.06. How were TherapeuticsMD's earnings last quarter? TherapeuticsMD, Inc. (NASDAQ:TXMD) announced its quarterly earnings data on Tuesday, August, 11th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($6.13) by $6.14. The business earned $0.87 million during the quarter, compared to analyst estimates of $19.77 million. TherapeuticsMD had a negative trailing twelve-month return on equity of 1.09% and a negative net margin of 6.64%. When did TherapeuticsMD's stock split? Shares of TherapeuticsMD reverse split on Monday, May 9th 2022.The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of TherapeuticsMD? Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TherapeuticsMD own? Based on aggregate information from My MarketBeat watchlists, some other companies that TherapeuticsMD investors own include Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK), Waste Connections (WCN), AUO (AUOTY) and The RMR Group (RMR). Company Calendar Last Earnings8/11/2026Today8/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 TXMD's financial health is in the Green zone, according to TradeSmith. TXMD has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TXMD Previous SymbolNYSEMKT:TXMD CIK25743 Webwww.therapeuticsmd.com Phone(561) 961-1900Fax561-431-3389Employees420Year Founded2008Profitability EPS (Trailing Twelve Months)$0.02 Trailing P/E Ratio103.00 Forward P/E RatioN/A P/E GrowthN/ANet Income-$570 thousand Net Margins-6.64% Pretax Margin-8.04% Return on Equity-1.09% Return on Assets-0.78% Debt Debt-to-Equity RatioN/A Current Ratio3.22 Quick Ratio3.22 Sales & Book Value Annual Sales$3.02 million Price / Sales7.89 Cash Flow$0.05 per share Price / Cash Flow43.51 Book Value$2.34 per share Price / Book0.88Miscellaneous Outstanding Shares11,570,000Free Float11,377,000Market Cap$23.83 million OptionableOptionable Beta0.61 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:TXMD) was last updated on 8/21/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TherapeuticsMD With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
